Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964426 | 0.87 | GPR119 (0.53) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5971305 | 0.86 | GPR119 (0.66) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2749734 | 0.86 | PDE4B (0.53) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL27088055 | 0.86 | F10 (0.51) | PDE4BEPHX2 | |
| SCHEMBL4460693 | 0.85 | PDE4B (0.54) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL15320871 | 0.85 | EPHX2 (0.47) | EPHX2 | |
| SCHEMBL19527650 | 0.84 | PDE4B (0.43) | GPR119PDE4BNR1H2EPHX2 | |
| SCHEMBL5971017 | 0.84 | PDE4B (0.67) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL5971118 | 0.84 | PDE4B (0.53) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL71246 | 0.84 | EPHX2 (0.56) | GPR119KDM1AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2833889-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| EP-1245564-B1 | BENZAMIDINE DERIVATIVES | SANKYO CO (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-6350761-B1 | INHIBITORS OF THE ENZYME, FACTOR XA; | BERLEX LABORATORIES, INC. | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | GPR119 1474/4885PDE4D 1427/4885PDE4B 855/4885 |
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | GPR119 1622/4885PDE4D 3926/4885PDE4B 3861/4885 |
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | GPR119 3838/4885PDE4D 4062/4885PDE4B 3983/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | GPR119 3852/4885PDE4D 4105/4885PDE4B 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.